# Artios Pharma funding rounds and investors

As of 14 Oct 2026, Artios Pharma has raised $115M across 1 verified round on record; latest: $115 million Series D led by RA Capital Management and SV Health Investors, announced 17 Nov 2025.

Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options.

Website: https://artios.com  
Page: https://fireround.dev/companies/artios.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-11-17 | Series D | $115 million | RA Capital Management, SV Health Investors | EQT Life Sciences, Novartis, Sofinnova Partners | [biopharmadive.com](https://www.biopharmadive.com/news/artios-cancer-dna-damage-atr-inhibitors-series-d/805459) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.